These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12604559)

  • 21. In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.
    Anderegg TR; Biedenbach DJ; Jones RN
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2662-4. PubMed ID: 12121951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).
    Barry AL; Fuchs PC; Brown SD
    Antimicrob Agents Chemother; 1998 Apr; 42(4):945-6. PubMed ID: 9559816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Streptococcus pneumoniae strains resistance to macrolide, lincosamide, streptogramin, oxazolidinone and ketolide].
    Sener B; Köseoğlu O; Fişenk I; Hasçelik G; Günalp A
    Mikrobiyol Bul; 2002 Apr; 36(2):125-31. PubMed ID: 12652863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis.
    Mulazimoglu L; Drenning SD; Yu VL
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2428-30. PubMed ID: 8891159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae.
    Mason EO; Lamberth LB; Kaplan SL
    Antimicrob Agents Chemother; 1996 Apr; 40(4):1039-40. PubMed ID: 8849225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
    Jones RN; Jenkins SG; Hoban DJ; Pfaller MA; Ramphal R
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):93-8. PubMed ID: 10863103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2003 Sep; 47(9):3012-4. PubMed ID: 12937016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristin.
    von Eiff C; Reinert RR; Kresken M; Brauers J; Hafner D; Peters G
    J Clin Microbiol; 2000 Aug; 38(8):2819-23. PubMed ID: 10921933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse effect of staphylococci slime on in vitro activity of glycopeptides.
    Mathur T; Singhal S; Khan S; Upadhyay D; Fatma T; Rattan A
    Jpn J Infect Dis; 2005 Dec; 58(6):353-7. PubMed ID: 16377866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ; Hershberger E; Moldovan T; Grucz RG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.
    Kosowska K; Hoellman DB; Lin G; Clark C; Credito K; McGhee P; Dewasse B; Bozdogan B; Shapiro S; Appelbaum PC
    Antimicrob Agents Chemother; 2005 May; 49(5):1932-42. PubMed ID: 15855516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activities of the oxazolidinone compounds linezolid (PNU-100766) and eperzolid (PNU-100592) against middle ear isolates of Streptococcus pneumoniae.
    Kearney JA; Barbadora K; Mason EO; Wald ER; Green M
    Int J Antimicrob Agents; 1999 Jul; 12(2):141-4. PubMed ID: 10418759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro activities of 16 non-beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
    Verhaegen J; Verbist L
    J Antimicrob Chemother; 1999 Apr; 43(4):563-7. PubMed ID: 10350388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vitro activity of sanfetrinem against isolates of Streptococcus pneumoniae and Staphylococcus aureus.
    Johnson AP; Warner M; Speller DC
    J Antimicrob Chemother; 1998 Nov; 42(5):643-6. PubMed ID: 9848449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ranbezolid, a novel oxazolidinone antibacterial: in vivo characterisation of monoamine oxidase inhibitory potential in conscious rats.
    Naruganahalli KS; Shirumalla RK; Bansal V; Gupta JB; Das B; Ray A
    Eur J Pharmacol; 2006 Sep; 545(2-3):167-72. PubMed ID: 16899241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial.
    Jones RN; Hare RS; Sabatelli FJ;
    J Antimicrob Chemother; 2001 Jan; 47(1):15-25. PubMed ID: 11152427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of Tedizolid phosphate against multidrug-resistant Streptococcus pneumoniae isolates from Asian countries.
    Baek JY; Kang CI; Kim SH; Ko KS; Chung DR; Peck KR; Hsueh PR; Thamlikitkul V; So TM; Lee NY; Song JH;
    Diagn Microbiol Infect Dis; 2016 Jun; 85(2):218-20. PubMed ID: 27083121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics.
    Oksuz L; Gurler N
    J Infect Dev Ctries; 2013 Nov; 7(11):825-31. PubMed ID: 24240040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci.
    John MA; Pletch C; Hussain Z
    J Antimicrob Chemother; 2002 Dec; 50(6):933-8. PubMed ID: 12461014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.
    Zurenko GE; Yagi BH; Schaadt RD; Allison JW; Kilburn JO; Glickman SE; Hutchinson DK; Barbachyn MR; Brickner SJ
    Antimicrob Agents Chemother; 1996 Apr; 40(4):839-45. PubMed ID: 8849237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.